Posted on

cbd and kidney failure

Jusqu’à ce que d’autres études soient menées, l’utilisation des cannabinoïdes non synthétiques chez les patients atteints d’IRC devrait se limiter au soulagement des douleurs neuropathiques chroniques. Les cliniciens doivent comprendre que les cannabinoïdes non synthétiques, particulièrement lorsqu’ils sont inhalés, comportent des risques significatifs pour la santé et que ceux-ci doivent être examinés avec prudence en regard des bienfaits thérapeutiques limités du cannabis chez les patients atteints d’IRC.

Justification:

Les symptômes physiques et psychologiques ressentis par les patients souffrant d’insuffisance rénale chronique (IRC) sont particulièrement débilitants, et souvent traités inadéquatement. La légalisation du cannabis au Canada pourrait susciter un intérêt croissant chez ces patients avec l’emploi médical de cette substance pour le traitement de ces symptômes. Cependant, les indications thérapeutiques du cannabis et ses effets nocifs sur la santé à long terme sont mal connus, rendant difficile son soutien par les cliniciens. L’article présente l’état des preuves et une synthèse des principales études cliniques portant sur l’usage des cannabinoïdes non synthétiques dans le traitement des symptômes fréquemment observés aux stades avancés de l’IRC, soit la douleur chronique, les nausées, les vomissements, l’anorexie, le prurit et l’insomnie.

Findings:

The focus of this article has been on nonsynthetic cannabis as opposed to synthetic cannabinoids such as dronabinol and nabilone, as the effects of isolated cannabinoids can be different from that produced by the whole plant. However, there are significant methodological challenges of studying nonsynthetic cannabis: standardization of drug delivery and exposure is poor due to the diversity of cannabis strains and their administration routes. Aside from nabiximols, which is available as a fixed dose of THC:CBD as an oromucosal spray, there is high variability in cannabis preparations in literature, which is further complicated by a lack of reporting of cannabis strains used. For studies that examine whole plant cannabis, dosage is frequently reported only based on proportion of THC, which limits guidance to the different effects of cannabis strains and hybridized breeds available. Variation in smoking techniques, such as depth and frequency of inhalation, can also lead to inconsistent drug delivery to study participants. Moreover, it is unclear whether administration methods such as vaporization, which spares the production of toxic combustion compounds by heating cannabinoids at a lower temperature, produce comparable efficacy and bioavailability of cannabinoids as smoking. Implementation of an effective placebo is also a significant barrier to conducting quality cannabis trials. Despite of double blinding of RCTs, psychotropic effects of THC are difficult to mask, particularly among experienced cannabis users; hence, risk for detection and performance bias is often high. The significant increase in THC potency from 3% to 12% since 1980s to 2012 in confiscated marijuana suggests that relevance of earlier studies with low potency cannabis may be limited, particularly with respect to long-term adverse effects. 116

Cbd and kidney failure

Another study , which was published in the Journal of Pharmacology and Experimental Therapeutics , showed that CBD might help reduce nephrotoxicity by decreasing oxidative stress, inflammation, and cell death (10 ) .

A 2016 review looked into the emerging role of the endocannabinoid system, particularly the cannabinoids and the cannabinoid receptors, in normal kidney function and other diseases, such as diabetes and obesity, that directly contribute to the development of renal diseases (14 ) .

When the kidneys fail, it means they have stopped working well enough for the person to survive without dialysis or a kidney transplant (1 ) .

How CBD Works: The Endocannabinoid System Explained

Kidney failure, also called renal failure or end-stage renal disease, is the last stage of chronic kidney disease.

Thus, therapeutic alternatives are in high demand, which may explain why, in recent years, medical marijuana has emerged as an attractive therapeutic option (11 ) .

CBD for Kidney Disease: What the Research Says

Findings suggested that short-term NSAID use has adverse side effects on blood pressure elevation (4 ) .

Marijuana and hemp belong to the s ame plant species, Cannabis sativa, but are widely different. Marijuana contains much more tetrahydrocannabinol (THC) than hemp, while hemp contains more cannabidiol (CBD).